**Nigeria Receives 11,520 Doses of Lenacapavir for HIV Prevention** In a significant development, Nigeria has taken delivery of 11,520 doses of Lenacapavir, a long-acting injectable medication for HIV prevention, courtesy of the Global Fund. The handover ceremony took place at the Federal Central Medical Stores in Oshodi, Lagos, marking a major milestone in the country's efforts to combat HIV/AIDS. Lenacapavir, recommended by the World Health Organization, is a twice-yearly injectable medication that offers an alternative to daily pills for HIV prevention. Its long-acting nature is expected to improve adherence to treatment, which is essential in preventing HIV transmission. This development is significant not just for Nigeria, but also globally, as it makes Nigeria one of the first nine countries to introduce Lenacapavir. According to the National AIDS, Viral Hepatitis, and STIs Control Programme (NASCP), a total of 52,000 doses are expected to be received, with additional batches scheduled for May and October. Under a pilot programme, the drug will be provided free of charge to selected participants who are at higher risk of HIV infection, including sero-discordant couples and sex workers. The programme aims to reach individuals in eight pilot locations: Kwara, Gombe, Anambra, Ebonyi, the Federal Capital Territory, Akwa Ibom, Cross River, and Benue. The introduction of Lenacapavir is a positive step towards expanding Nigeria's HIV prevention options. As the country continues to grapple with the challenges of HIV/AIDS, this development offers hope for those living with the virus and those at risk of infection. The NASCP representative, Mohammed Patiko, described the development as a major milestone, highlighting the potential of Lenacapavir to improve adherence to treatment and prevent HIV transmission. As Nigeria takes this significant step forward, it is essential to spread the word about the availability of this new medication and ensure that those who need it have access to it. With this new development, Nigeria is taking a bold step towards addressing the HIV/AIDS epidemic, and it is hoped that this will lead to a reduction in new infections and an improvement in the overall health outcomes of those affected by the virus.